WHO Raises Concern Over Critical Scarcity of Weight-Loss Jabs

Fewer than a tenth of patients who could benefit from weight-loss injections like Wegovy can access them, caution the World Health Organization as it releases its initial guidance on the therapies.

Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for broader and more equitable access to GLP-1 medication.

Based on projections, over two billion could be obese by 2030 without intervention.

"Our latest guidelines affirms that obesity is a lifelong illness that can be managed with holistic and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and logistical bottlenecks are significant obstacles to broad access to the injections that can help people shift substantial body mass, says the body.

Skinny Jab Scarcity

Despite the present best projected scenario, the manufacturing of GLP-1 therapies could only cover about 100 million people – under 10% of the global need, according to the WHO.

The guideline urges countries and companies to expand availability, by approaches like licensing agreements.

Exclusive production rights on the active ingredient – the core ingredient of a leading brand – is due to expire in a number of nations in 2026.

The Way Obesity Jabs Work

These medications imitate a body's own hormone to reduce digestion speed, reduce hunger and boost feelings of fullness so individuals reduce food intake.

Patients usually see weight reduction within a few weeks of starting on the once-weekly jabs.

Studies suggests patients may put most of the weight back on a year later of halting the drug, when their typical appetite return.

To be overweight or obese raises your chance for contracting diseases, like diabetes, cardiovascular issues, brain attack, and certain malignancies.

Excess weight concerns individuals in countries worldwide and was associated with millions of deaths worldwide in 2024, per the WHO.